Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) said it expanded its phase II study of its SCIB1 vaccine treatment for an advanced form of skin cancer – a move that will broaden the patient population and accelerate recruitment.
The new cohort in the SCOPE study will consist of people with metastatic melanoma receiving checkpoint doublet therapy along with the company’s drug. That ‘doublet’ consists of existing treatments Yervoy and Opdivo.
The first group received SCIB1 along with another checkpoint inhibitor, Keytruda. The therapeutic payload will be delivered using PharmaJet’s needle-free injection system.
Investors were told Scancell remains on track to deliver initial efficacy data this year.
“We believe that SCIB1 administration in combination with doublet therapy has the potential to offer greater efficacy than checkpoint inhibitors alone, without increasing toxicity," chief executive, professor Lindy Durrant, said.